Spartacus Acquisition Corporation Class A Common Stock
TMTS
TMTS was delisted on the 28th of October, 2021.
0 hedge funds and large institutions have $0 invested in Spartacus Acquisition Corporation Class A Common Stock in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.
100% less funds holding
Funds holding: 51 → 0 (-51)
100% less capital invested
Capital invested by funds: $181M → $0 (-$181M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 50
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$34.2M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$16.1M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$12.5M |
| 4 |
GCL
Glazer Capital LLC
New York
|
-$11.4M |
| 5 |
KC
Kepos Capital
New York
|
-$7.84M |
TMTS Hedge Fund Activity: Q4 2021 in Review
0 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Spartacus Acquisition Corporation Class A Common Stock (TMTS) for Q4 2021, worth a combined $0 — down 100% from $181M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of TMTS and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Karpus Investment Management, exiting entirely with an estimated $34.2M sold.
- 0 institutional investors held Spartacus Acquisition Corporation Class A Common Stock (TMTS) as of Q4 2021, down from 51 in Q3 2021.
- Funds reported $0 of Spartacus Acquisition Corporation Class A Common Stock stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Spartacus Acquisition Corporation Class A Common Stock positions in Q4 2021 and 50 closed out, a net change of -50 holders.
- The largest Spartacus Acquisition Corporation Class A Common Stock seller in Q4 2021 was Karpus Investment Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q4 2021.